Glycobiology, 2000, Vol. 10, No. 2 173-176
© 2000 Oxford University Press
Glycotyping of prostate specific antigen
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Measurement of serum levels of the prostate specific antigen (PSA) is now widely used for the diagnosis of prostate cancer and benign prostate hyperplasia. This serum marker is of value since it is derived only from the tissue of interest, but increased levels of PSA in serum do not allow a completely clear cut diagnosis of benign versus malignant changes. Since PSA is a glycoprotein with one asparagine linked oligosaccharide, and since malignant transformation often leads to an increased branching of such oligosaccharides, we initially studied the asparagine linked structures on PSA made by a cell line derived from malignant metastatic prostate tissue. We observed that unlike normal PSA, which bears only biantennary oligosaccharides, PSA from the metastatic cell line has a mixture of biantennary and triantennary oligosaccharides. Further experiments will reveal carbohydrate differences derived from the PSA from sera or, prostate tissue of normal versus prostate cancer patients, and of the utility of such carbohydrate differences as a possible diagnostic marker for prostate cancer.
1 To whom correspondence should be addressed at: c/o Dr. P.W.Robbins, Center for Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building E-17, Room 130, Cambridge, MA 02139
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Tajiri, C. Ohyama, and Y. Wada Oligosaccharide Profiles of the Prostate Specific Antigen in Free and Complexed Forms from the Prostate Cancer Patient Serum and in Seminal Plasma: a Glycopeptide Approach Glycobiology, January 1, 2008; 18(1): 2 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tabares, C. M. Radcliffe, S. Barrabes, M. Ramirez, R. N. Aleixandre, W. Hoesel, R. A. Dwek, P. M. Rudd, R. Peracaula, and R. de Llorens Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA Glycobiology, February 1, 2006; 16(2): 132 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ohyama, M. Hosono, K. Nitta, M. Oh-eda, K. Yoshikawa, T. Habuchi, Y. Arai, and M. Fukuda Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy Glycobiology, August 1, 2004; 14(8): 671 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Peracaula, G. Tabares, L. Royle, D. J. Harvey, R. A. Dwek, P. M. Rudd, and R. de Llorens Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins Glycobiology, June 1, 2003; 13(6): 457 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text] |
||||


